This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Fred Khosravi and AccessClosure (C)
Hamermesh, Richard G.; Barley, LaurenCase HBS-814074-EEntrepreneurshipOn September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the company. The future looked bright for AccessClosure as 2013 drew to a close. The company expected 2014 revenues of more than $100 million with a gross margin of greater than 70%. It wa...Starting at €5.74
-
Whose Money Is It Anyway (C)
Narayanan, V.G.; Hamermesh, Richard G.; Gordon, RachelCase HBS-810031-EAccounting and ControlThe case describes how the Brigham and Women's Physicians Organization and its corporate parent resolved the issue of how the disputed funds would be distributed and used.Starting at €5.74
-
Whose Money Is It Anyway (A), (B), and (C), Teaching Note
Hamermesh, Richard G.; Narayanan, V.G.; Gordon, RachelTeaching Note HBS-111128-EAccounting and ControlTeaching Note for 810-008, 810-013, and 810-031.Starting at €0.00
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Case HBS-302S36Knowledge and CommunicationDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Starting at €8.20
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCase HBS-815114-EEntrepreneurshipIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Starting at €8.20
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCase HBS-813091-EEntrepreneurshipSupplement for case 809011Starting at €8.20
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCase HBS-818068-EStrategyStarting at €8.20
-
Bloodbuy, Teaching Plan
Hamermesh, Richard G.; Quelch, John A.; Norris, MichaelTeaching Note HBS-815140-EEntrepreneurshipTeaching plan for case 815114.Starting at €0.00
-
DentalCorp, Teaching Note
Hamermesh, Richard G.; Seefeld, ErinTeaching Note HBS-807163-EEntrepreneurshipTeaching Note to (806-023).Starting at €0.00